Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0KBCEN)
| ADC Name |
M3554
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
M3554; M3354
Click to Show/Hide
|
|||||
| Organization |
Merck KGaA (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-GD2 antibody
|
Antibody Info | ||||
| Antigen Name |
Ganglioside GD2 (GD2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-glucuronide-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
tocentecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Brain cancer |
1 Trials
|
|||||
| Sarcoma |
1 Trials
|